KDM1A and melanoma: Although global changes in the chromatin landscape have been noted during tumor progression in melanoma (5, 6), and histone H3 demethylases, including LSD1, have been shown to promote multidrug resistance (8, 36) and bypassing of oncogene-induced senescence (53), the specific targeting of these pathways has not led to meaningful clinical effects to date, while targeting of the HDACs in the setting of MAPKi resistance in melanoma has also failed to yield significant therapeutic benefits (54–56).